IP Verse

Pharmaceutical Formulations Comprising 1 - (Beta-D-Glucopyranosyl) - 2 -Thienylmethylbenzene Derivatives As Inhibitors Of Sglt

Patent No. EP2568988 (titled "Pharmaceutical Formulations Comprising 1 - (Beta-D-Glucopyranosyl) - 2 -Thienylmethylbenzene Derivatives As Inhibitors Of Sglt") was filed by Janssen Pharmaceutica on May 11, 2011. The application was issued on Jul 13, 2016.

Patent Summary

Patent Family

Patent family tree
Statuses, jurisdictions and citation links are shared on request.

Patent Oppositions

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentative
LEK PHARMACEUTICALS DDApr 13, 2017MAIWALD PATENT- UND RECHTSANWALTSGESELLSCHAFT MBH

Dossier Documents

The dossier documents provide a comprehensive record of the patent's prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent's legal journey and any challenges it may have faced during examination.

  • Date

    Description

EP2568988

JANSSEN PHARMACEUTICA
Application Number
EP11721616A
Filing Date
May 11, 2011
Status
Revoked
Mar 16, 2022
Publication Date
Jul 13, 2016
External Links
Slate, Register , Google Patents